

**Veripad Inc.**  
2112 43<sup>rd</sup> street  
Astoria, NY 11105

*Bishoy Ghobryal*  
www.veripad.co  
bishoy@veripad.co



**Industry:**

- \_\_\_\_ Pharma
- \_\_\_\_ Biotech
- \_\_\_\_ Medical Device
- \_\_\_\_ Diagnostic
- Health IT, Portable chemistry

**Management:**

- Executive Leadership  
Bishoy Ghobryal, CEO  
Da Wi Shin, COO  
Y-Lan Nguyen, CAO  
Jason Ki, CTO
  
- Board of Advisors  
Jason Leder, Google  
Karina Fassbender, Merck  
Pierre Nicolas, BNY Mellon  
Mayerlin Kanterman, BNY Mellon  
Nathan Sigworth, PharmaSecure  
Alden Zecha, Sproxil  
Kim Wales, Wales Capital Crowd  
Bureau
  
- Scientific Advisory Board  
Dr. Marya Lieberman, UND

**Number of Employees:** 4

**Finance:**

- Financing to Date  
Zahn Innovation Center: \$25,000  
BNY Mellon: \$4,000  
Merck KgAa: \$50,000  
Grand Challenges Canada:  
\$60,000  
MassChallenge: \$50,000
  
- Amount of Financing Sought:  
\$.5M

**Legal:**

- IP: Brendan Mee, Pearl Cohen

**Executive Summary:**

Veripad is a health IT company that has created a disruptively affordable and easy-to-use solution to identify common counterfeit and falsified medicines. Counterfeit medicines are a growing global problem, with the WHO estimating that 30 to 50% of medicines worldwide are suspect. Veripad is positioned to protect affected populations through novel technologies and actionable policies.

**Company History:**

The Veripad team understands the importance of high quality medications through personal experience, and strives to improve access to safe drugs worldwide. Since 2014, our team of diverse and experienced professionals in biomedical engineering and healthcare, aims to provide a lasting solution to one of the biggest problems facing the world today.

**Market Opportunity / Unmet Need:**

While fake medications can be found in every country, it disproportionately affects low to middle income countries where up to 30% of medicines are falsified compared to 1% in developed countries. Unfortunately, most of those in need do not have resources to counter the epidemic. In developed nations, pharmaceutical companies lose money to counterfeiters who hi-jack their brand and sell substandard medicines online. Veripad offers a comprehensive, simple solution that can be executed with minimal training, allowing anyone, anywhere to safely detect suspicious medicines

**Products/Services – Launched & Pipeline:**

Paper Analytical Device (PAD): Small test card with chemical reagents preloaded to authenticate components of a specific medication  
Companion app: Smartphone app that processes and interprets results of PAD, in seconds  
Data: In 2020, worldwide data from our clients' testing will be monetized

**Commercial / Technical Milestones:**

**2018:** Manufacturing facility established in Kenya, new chemical tests added  
**2019:** iOs companion app & launch quantitative test cards  
**2020:** Automate manufacturing process & implement data collection and reporting

**Intellectual Property:**

Paper Analytical Devices (PADs)

**Competition:**

TruScan- handheld spectroscopy device  
Sproxil- serial barcode authentication technology  
Sirche- simple chemical authentication reagents in pouches

**Financial Projections (Unaudited):**

**2021:** Break-even point  
**2022:** \$4 M USD in revenue

**Please indicate primary purpose of Presentation:**

Investment  
Business Development  
Other: (Please specify)